Clinical Trials on Crohn´s Disease in Canada

Total 25126 results

Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

Crohn Disease

Belgium, United States, Japan, Czechia, Hungary, Korea, Republic of, France, Taiwan, Germany, Malaysia, New Zealand, Poland, Canada, Turkey, Croatia, Israel, China, Denmark, Netherlands, Brazil, Italy, Spain, Jordan, Bosnia and Herzegovina and more
AstraZeneca
MedImmune Ltd

Completed

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn's Disease

United States, France, Italy, Poland, Germany, Spain, Canada, Hungary, Czechia
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
Hoffmann-La Roche

Terminated

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Crohn Disease

United States, Israel, Spain, United Kingdom, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Korea, Republic of, Germany, Bulgaria, Croatia, Hungary, Poland, Ukraine and more
Celgene

Active, not recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Italy, Germany, Russian Federation, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Georgia, India, Ireland, Israel, Korea, Republic... and more
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
AstraZeneca

Terminated

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Crohn's Disease

United States, France, Italy, Belgium, Australia, Canada, Hungary, Russian Federation, Spain, Germany, Netherlands, Israel
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

Crohn's Disease

United States, Denmark, Belgium, Taiwan, Italy, Korea, Republic of, Germany, United Kingdom, Israel, Malaysia, Poland, Japan, New Zealand, Netherlands, China, Canada, France, Spain, Norway, Singapore, Croatia, Brazil, Switzerland, Aus... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Crohn's Disease

United States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, Turkey, China, United Kingdom and more
Eli Lilly and Company

Recruiting

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

Crohn's Disease

United States, Japan, India, Canada, Turkey, Ukraine, Brazil, Mexico, Korea, Republic of, Croatia, Hungary, Latvia, Lithuania, Serbia, China, Australia, Poland, Israel, Czechia, Slovakia, Switzerland, Russian Federation, Germany, Austria and more
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Centocor, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Crohn's Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
Emory University
Crohn's and Colitis Foundation

Completed

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease (RS)

Crohn's Disease

United States, Canada
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)

United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
Jamp Pharma Corporation

Recruiting

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications. (EASE PAIN)

Rheumatoid Arthritis | Plaque Psoriasis | Crohn Disease | Ulcerative Colitis | Hidradenitis Suppurativa | Psoriatic Arthritis | Ankylosing Spondylitis

Canada
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Australia, France, Taiwan, Hungary, Korea, Republic of, Spain, Switzerland, China, Japan, Belgium, Canada, Germany, Italy, Poland, Romania, United Kingdom, Czechia, Denmark, Greece, Norway, Slovakia, Netherlands
Pfizer

Completed

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease (ONWARD)

Inflammatory Bowel Disease (IBD) | Ulcerative Colitis (UC) | Crohn's Disease (CD)

United States, Canada
UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
AbbVie

Completed

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

Crohn's Disease

United States, France, Netherlands, Spain, Germany, Poland, Belgium, South Africa, Sweden, Israel, Korea, Republic of, Australia, Austria, Canada, Czechia, Denmark, Hungary, Italy, Japan, New Zealand, Norway, Slovakia, United Kingdom
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, South... and more
GlaxoSmithKline

Terminated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

Crohn's Disease

United States, France, Netherlands, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New... and more
GlaxoSmithKline

Terminated

Open-Label Extension Study of GSK1605786A (SHIELD-3)

Crohn's Disease

United States, France, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New Zealand, Po... and more
Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Australia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Belgium, Hungary, Croatia, ...
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Takeda

Terminated

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment (CALYPSO)

Gastrointestinal Diseases | Intestinal Diseases | Crohn Disease | Inflammatory Bowel Disease

Spain
Alpine Immune Sciences, Inc.

Completed

Cell Surface Marker Expression in Autoimmune Diseases (CASCADE)

Multiple Sclerosis | Systemic Lupus Erythematosus | Systemic Sclerosis | Crohn's Disease | Ulcerative Colitis | Sjogren's Syndrome | Inflammatory Myositis

Canada
Tigenix S.A.U.

Completed

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) (ADMIRE-CD-II)

Crohn's Disease

United States, Spain, United Kingdom, Italy, Germany, Canada, Belgium, Denmark, Poland, Czechia, France, Hungary, Israel, Puerto Rico, Sweden
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
Janssen Biotech, Inc.

Terminated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Crohn's Disease

United States, France, United Kingdom, Germany, Belgium, Australia, Israel, Canada, Netherlands, New Zealand, Czech Republic, Austria, Poland, Hungary
Bristol-Myers Squibb

Completed

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Romania, Italy, United States, Australia, Canada, China, Germany, Hungary, Japan, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom
Takeda

Completed

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease (GEMINI LTS)

Crohn's Disease | Ulcerative Colitis

Belgium, United States, Korea, Republic of, Malaysia, Canada, Israel, Australia, Hungary, Czechia, Germany
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease (CONNECT-IBD)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis

France, Spain, United Kingdom, Czechia, Italy, Belgium, Germany, Netherlands, Greece, Finland, Hungary, Portugal, Slovakia
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)

Crohn Disease | Colitis, Ulcerative

United States, Bulgaria, Czechia, Hungary, Poland, Spain, Belgium, France, Italy, Japan, Norway, Slovakia, Germany, Canada, Ukraine, United Kingdom, Israel, Serbia
RedHill Biopharma Limited

Completed

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (MAPUS2)

Crohn Disease

United States, Canada, Czechia, Israel, New Zealand, Poland, Serbia
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
Takeda

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Belgium, Australia, Israel, United States, Hungary, Korea, Republic of, China, Canada, Croatia, Italy, Poland, Slovakia, United Kingdom, Japan, Greece
Takeda
Takeda Development Center Americas, Inc.

Completed

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Israel, United States, Hungary, Belgium, Canada, United Kingdom, Germany, Netherlands, Poland, Ukraine, France
Takeda

Active, not recruiting

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Crohn's Disease | Colitis, Ulcerative

United States, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Netherlands, Australia, Denmark, Hungary, Italy, Russian Federation, Brazil, Croatia, Germany, Serbia, Bulgaria, Canada, Poland, Slovakia, Ukraine, Czechia, Argentina, Turke... and more
Circassia Limited
Adiga Life Sciences, Inc.

Completed

ToleroMune Grass Follow on Study

Grass Allergy | Rhinoconjunctivitis

Canada
Université de Sherbrooke
Canadian Institutes of Health Research (CIHR); Western University, Canada; Agence...

Completed

Patient-Centred Innovations for Persons With Multimorbidity - Quebec (PACEinMM-QC)

Depression | Heart Failure | Stroke | Hypertension | Cardiovascular Disease | Diabetes | Ulcer | Cancer | Arthritis | Rheumatoid Arthritis | Musculoskeletal Pain | Asthma | Gastroesophageal Reflux | Dementia | Anxiety | HIV | Crohn's Disease | Osteoporosis | Ulcerative Colitis | Chronic Obstructive Pulmonary Disease (COPD) | Hyperlipi... and other conditions

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Ragweed-SPIRE Follow-On Study

Rhinoconjunctivitis | Ragweed Allergy

Canada
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more

Clinical Trials on Crohn´s Disease in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations